According to Emergent BioSolutions 's latest financial reports the company's current revenue (TTM) is $1.02 B. In 2022 the company made a revenue of $1.07 B a decrease over the years 2021 revenue that were of $1.65 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $1.02 B | -5.15% |
2022 | $1.07 B | -34.92% |
2021 | $1.65 B | 15.15% |
2020 | $1.44 B | 46.45% |
2019 | $0.98 B | 39.44% |
2018 | $0.70 B | 43.81% |
2017 | $0.49 B | 41.99% |
2016 | $0.34 B | -12.21% |
2015 | $0.39 B | 15.96% |
2014 | $0.33 B | 31.55% |
2013 | $0.25 B | 51.61% |
2012 | $0.17 B | -37.77% |
2011 | $0.27 B | -4.47% |
2010 | $0.28 B | 21.89% |
2009 | $0.23 B | 31.49% |
2008 | $0.17 B | -2.38% |
2007 | $0.18 B | 5.76% |
2006 | $0.17 B | 32.34% |
2005 | $0.13 B | 56.52% |
2004 | $83.49 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 5,613.71% | ๐บ๐ธ USA |
Merck MRK | $60.11 B | 5,771.65% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $37.84 B | 3,596.92% | ๐ฌ๐ง UK |
Soligenix SNGX | $0.83 M | -99.92% | ๐บ๐ธ USA |
SIGA Technologies SIGA | $0.13 B | -86.33% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $6.88 M | -99.33% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $15.84 B | 1,447.76% | ๐ฎ๐ฑ Israel |